SSC
MRNA icon

Syverson Strege & Co’s Moderna MRNA Stock Holding History

Syverson Strege & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-36
Closed -$5.53K – 408
2023
Q1 		$5.53K Buy
+36
New +$5.94K ﹤0.01% 319
2021
Q4 		– Sell
-56
Closed -$22K – 421
2021
Q3 		$22K Buy
+56
New +$20.7K 0.02% 188

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Syverson Strege & Co's MRNA Position: Q2 2023 in Review

Syverson Strege & Co sold out of Moderna (MRNA) in Q2 2023, closing a stake of 36 shares — an estimated $5.53K sold.

Syverson Strege & Co first reported a position in MRNA in Q3 2021 and held it in 2 quarters. The position peaked at $22K in Q3 2021. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Syverson Strege & Co reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Syverson Strege & Co sold 36 Moderna shares in Q2 2023, an estimated $5.53K.
  • Syverson Strege & Co first reported a position in Moderna in Q3 2021 and held it in 2 quarters.
  • Syverson Strege & Co's Moderna position peaked at $22K in Q3 2021.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.